Heidelberg Pharma AG
HPHA.DEDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
124-Iodine-cG250 (124I-cG250)
Renal Cell Carcinoma
girentuximab
Kidney Cancer
HDIT101
Herpes Genitalis
WX-671
Metastatic Breast Cancer
gemcitabine hydrochloride
Pancreatic Cancer
HDP-101
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
124-Iodine-cG250 (124I-cG250) | Phase 3 | Renal Cell Carcinoma | - | - |
girentuximab | Phase 3 | Kidney Cancer | - | - |
HDIT101 | Phase 2 | Herpes Genitalis | - | - |
WX-671 | Phase 2 | Metastatic Breast Cancer | - | - |
gemcitabine hydrochloride | Phase 2 | Pancreatic Cancer | - | - |
HDP-101 | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in Heidelberg Pharma AG's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Heidelberg Pharma AG's (HPHA.DE) pipeline across Phase 3, Phase 2. Its lead program is 124-Iodine-cG250 (124I-cG250) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Heidelberg Pharma AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Heidelberg Pharma AG (HPHA.DE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HPHA.DE biotech catalysts?→
Add HPHA.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Heidelberg Pharma AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.